Jonathan G.  Drachman net worth and biography

Jonathan Drachman Biography and Net Worth

Dr. Drachman is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington.

What is Jonathan G. Drachman's net worth?

The estimated net worth of Jonathan G. Drachman is at least $5.78 million as of August 24th, 2021. Dr. Drachman owns 117,434 shares of Neoleukin Therapeutics stock worth more than $5,784,799 as of March 28th. This net worth evaluation does not reflect any other assets that Dr. Drachman may own. Learn More about Jonathan G. Drachman's net worth.

How do I contact Jonathan G. Drachman?

The corporate mailing address for Dr. Drachman and other Neoleukin Therapeutics executives is 1616 EASTLAKE AVE EAST SUITE 360, SEATTLE WA, 98102. Neoleukin Therapeutics can also be reached via phone at (866) 245-0312 and via email at [email protected]. Learn More on Jonathan G. Drachman's contact information.

Has Jonathan G. Drachman been buying or selling shares of Neoleukin Therapeutics?

Jonathan G. Drachman has not been actively trading shares of Neoleukin Therapeutics within the last three months. Most recently, on Tuesday, August 24th, Jonathan G. Drachman bought 5,000 shares of Neoleukin Therapeutics stock. The stock was acquired at an average cost of $122.20 per share, with a total value of $611,000.00. Following the completion of the transaction, the chief executive officer now directly owns 117,434 shares of the company's stock, valued at $14,350,434.80. Learn More on Jonathan G. Drachman's trading history.

Who are Neoleukin Therapeutics' active insiders?

Neoleukin Therapeutics' insider roster includes Jonathan Drachman (CEO), and Carl Walkey (SVP). Learn More on Neoleukin Therapeutics' active insiders.

Are insiders buying or selling shares of Neoleukin Therapeutics?

During the last year, Neoleukin Therapeutics insiders bought shares 2 times. They purchased a total of 102,787 shares worth more than $1,305,132.60. During the last year, insiders at the sold shares 2 times. They sold a total of 254 shares worth more than $3,412.80. The most recent insider tranaction occured on August, 17th when Director Bros. Advisors Lp Baker bought 8,347 shares worth more than $115,188.60. Insiders at Neoleukin Therapeutics own 1.6% of the company. Learn More about insider trades at Neoleukin Therapeutics.

Information on this page was last updated on 8/17/2023.

Jonathan G. Drachman Insider Trading History at Neoleukin Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/24/2021Buy5,000$122.20$611,000.00117,434View SEC Filing Icon  
6/3/2021Buy2,000$189.60$379,200.00111,934View SEC Filing Icon  
12/20/2019Buy5,952$168.00$999,936.00View SEC Filing Icon  
See Full Table

Jonathan G. Drachman Buying and Selling Activity at Neoleukin Therapeutics

This chart shows Jonathan G Drachman's buying and selling at Neoleukin Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Neoleukin Therapeutics Company Overview

Neoleukin Therapeutics logo
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Read More

Today's Range

Now: $50.90
Low: $46.69
High: $52.50

50 Day Range

MA: $34.15
Low: $29.14
High: $49.88

2 Week Range

Now: $50.90
Low: $2.03
High: $14.36

Volume

346,901 shs

Average Volume

50,104 shs

Market Capitalization

$478.36 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.11